Lynnetta Payne, DO
Urology · Beckley, WVNPI 1366636763
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Medtronic at 45.1% of the total. Reporting peaked in 2019 at $7,446 and has fallen 86.5% since, to $1,004 in 2025. Among urology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $62.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Procept Biorobotics Corporation$4K
- EDAP Technomed Inc$2K
- Astellas Pharma US Inc$1K
- Pfizer$776
- Neotract Inc.$579
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$7,12031%
- Travel & lodging$5,49724%
- Food & beverage$10,10544%
- Education$3001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 52 | $10,390 |
| Procept Biorobotics Corporation | 38 | $3,910 |
| EDAP Technomed Inc | 3 | $1,671 |
| Astellas Pharma US Inc | 61 | $1,255 |
| Pfizer | 39 | $776 |
| Neotract Inc. | 17 | $579 |
| Teleflex LLC | 13 | $423 |
| Axonics, Inc. | 13 | $422 |
| Ambu Inc. | 7 | $413 |
| Boston Scientific | 10 | $378 |
| AbbVie(2 entities) | 17 | $321 |
| Coloplast | 10 | $321 |
| Bayer | 13 | $264 |
| Organogenesis Inc. | 5 | $238 |
| Myriad Genetic Laboratories, Inc. | 9 | $188 |
| Endo USA, Inc. | 7 | $185 |
| Urovant Sciences Inc | 7 | $129 |
| Johnson & Johnson | 6 | $124 |
| Olympus America Inc. | 5 | $107 |
| Dornier Medtech America, Inc | 1 | $103 |
| Sumitomo Pharma America, Inc. | 5 | $101 |
| Urogen Pharma, Inc. | 4 | $94 |
| SRS Medical Systems, Inc. | 2 | $78 |
| Merck | 4 | $75 |
| Novo Nordisk | 1 | $73 |
| Laborie Medical Technologies Corp. | 2 | $60 |
| Myovant Sciences Inc. | 3 | $55 |
| Abbott | 1 | $49 |
| Blue Earth Diagnostics | 2 | $41 |
| Endo Pharmaceuticals Inc. | 2 | $40 |
| Novartis | 2 | $36 |
| Telix Pharmaceuticals | 1 | $24 |
| Convatec Inc. | 1 | $21 |
| Davol Inc. | 1 | $21 |
| Hollister Incorporated | 1 | $18 |
| Smith+Nephew | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$9,161
- AQUABEAM SYSTEM$2,734
- TITAN$126
- ALTAVIVA$120
- GENERAL BPH$116
- Axonics$103
- Dornier MedTech$103
How this compares
$23,023 in reported general payments places this provider in the 95th percentile of 67 urology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 63 | $35,457 |
| GemtesaVibegron | 32 | $22,614 |
| Trimethoprim | 39 | $2,123 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 45 | $1,735 |
| Solifenacin Succinate | 32 | $1,158 |
| Trospium Chloride | 25 | $885 |
| Tamsulosin Hcl | 148 | $821 |
| Estradiol | 14 | $739 |
| Silodosin | 26 | $690 |
| Cephalexin | 145 | $541 |
| Finasteride | 61 | $516 |
| Oxybutynin Chloride ErOxybutynin Chloride | 37 | $510 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $361 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 45 | $261 |
| SsdSilver Sulfadiazine | 11 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,255 | $35,45763 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $101 | $22,61432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 urology providers in West Virginia.
Other urology in Beckley
- Jaschar Shakuri-RadMorgantown$77K
- Ali HajiranMorgantown$37K
- Stanley ZaslauHuntington$14K
- John BarnardMorgantown$10K
- Mohamad SalkiniMorgantown$8K
- Joshua LohriCharleston$8K
- Nathan HaleCharleston$7K
- Rocco MorabitoHuntington$6K
- Samuel DeemCharleston$6K
- Kyle FortRonceverte$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.